The Current and Potential Clinical Relevance of Heart Failure Biomarkers.
The Current and Potential Clinical Relevance of Heart Failure Biomarkers.
复制标题
DOI：
10.1007/s11897-015-0268-2
复制
发表时间：
2015-10-01
影响因子：
--
通讯作者：
Ahmad, Tariq
中科院分区：
文献类型：
--
作者：
Gandhi, Parul U;Testani, Jeffrey M;Ahmad, Tariq
心力衰竭是一种日益流行的疾病，我们对其病理生理学复杂性的理解也在不断发展。在过去的十年中，心力衰竭的生物标志物已经被广泛研究，特别是在诊断和风险分层方面。虽然利钠肽仍然是心力衰竭生物标志物的金标准，但它们的非特异性使它们受到困扰；此外，利钠肽引导护理的策略仍然难以捉摸。已经确定和研究了多种指示心力衰竭其他生理方面的候选标志物，包括可溶性ST2、半乳糖凝集素-3和高敏感性心肌肌钙蛋白。这些生物标记物中的每一种都有可能提供独特的治疗相关信息。最终，一种多标志物的方法可以用于改善心力衰竭患者的护理。需要明确的临床试验和使用先进的统计分析技术，以真正确定生物标志物辅助诊断、预测和管理患有这种毁灭性疾病的患者的最佳策略。
Heart failure is a growing epidemic, and our understanding of the intricacies of its pathophysiology continues to evolve. Over the last decade, biomarkers of heart failure have been extensively investigated, particularly for diagnosis and risk stratification. While the natriuretic peptides remain the gold standard heart failure biomarker, they are plagued by their non-specific nature; furthermore, the strategy of natriuretic peptide-guided care remains elusive. Multiple candidate markers indicative of other physiologic aspects of heart failure have been identified and studied, including soluble ST2, galectin-3, and high-sensitivity cardiac troponins. Each of these biomarkers has the potential to provide unique therapeutically relevant information. Ultimately, a multi-marker approach may be applied to improve care of patients with heart failure. Definitive clinical trials and the use of advanced statistical analytic techniques are needed to truly determine the optimal strategy of biomarker-assisted diagnosis, prognostication, and management of patients who suffer from this devastating condition.